BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 31

• Drug Development

  Saghmos Therapeutics Announces Receipt of Notice of Allowance from Japanese Patent Office for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516

  Saghmos Therapeutics, Inc. announced that it has received a Notice of Allowance from the Japanese Patent Office for a patent for its Phase 3-ready product, ST-62516.

  March 12, 2024

   · 

  3 min read
• Business

  Immunovia announces updated financial calendar - March 12, 2024

  Immunovia updates its financial calendar for 2024.

  March 12, 2024

   · 

  1 min read
• Business

  GV20 Therapeutics Joins NVIDIA Inception to Develop AI Models for Drug and Target Discovery

  GV20 Therapeutics announced today that it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements.

  March 12, 2024

   · 

  1 min read
• Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204

  Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today reported promising interim results from its study on MB-204

  March 12, 2024

   · 

  5 min read
• Business

  Intrommune Therapeutics Strengthens Board of Directors with Appointments of Dr. Jonathan Rich and Hem Pandya

  Intrommune Therapeutics today announced the appointment of Dr. Jonathan Rich to its board of directors and Hem Pandya as Executive Chairman of the board of directors.

  March 12, 2024

   · 

  5 min read
• Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution

  Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is voluntarily recalling one lot of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level.

  March 12, 2024

   · 

  4 min read
• Policy

  FDA Roundup: March 12, 2024

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

  March 12, 2024

   · 

  2 min read
• Business

  iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results

  iCAD, Inc. (NASDAQ: ICAD) today announced results for its fiscal fourth quarter and full year ended December 31, 2023, as compared to the corresponding period of the last fiscal year.

  March 12, 2024

   · 

  21 min read
• Biotech Beach

  Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT Registry

  Inari Medical, Inc. a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive two-year interim results from the CLOUT registry.

  March 12, 2024

   · 

  3 min read
• Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days

  Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Stifel 2024 Virtual CNS Days event.

  March 12, 2024

   · 

  1 min read